SR One co-led antibody therapy developer Ancora Biotech's $60m series A round while Al-Dhow Engineering helped coffee chain Flash Coffee secure $32.8m.

Funding Ancora Biotech, a Switzerland-based developer of antibody-driven therapeutics, has raised $60m in a series A round co-led by SR One, the venture capital firm spun off by pharmaceutical firm GlaxoSmithKline, and private equity firm Lightspeed Venture Partners. Stake sale Consumer intelligence software provider Affle Global has paid approximately $11.8m for an additional 13.1% stake…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.